Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SUVN-G3031 (samelisant), potent and selective histamine H3 receptor inverse agonist, is being developed for the treatment of excessive daytime sleepiness (EDS) in adult narcolepsy patients with and without cataplexy.
Lead Product(s): Samelisant
Therapeutic Area: Sleep Product Name: SUVN-G3031
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2024
Details:
SUVN-502 (masupirdine) is a novel, potent, pure, and orally active 5-HT6 receptor antagonist, it is being investigated as a potential therapy against alzheimer's disease.
Lead Product(s): Masupirdine,Donepezil,Memantine Hydrochloride
Therapeutic Area: Neurology Product Name: SUVN-502
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2023
Details:
SUVN-502 (Masupirdine), a lead clinical candidate having undergone phase 2 study on 564 patients for moderate Alzheimer’s disease without meeting primary end point.
Lead Product(s): Masupirdine,Donepezil,Memantine Hydrochloride
Therapeutic Area: Neurology Product Name: SUVN-502
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2021